HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

13.52 -0.27 (-1.99%)

Streaming Delayed Price Updated: 9:59 AM EDT, Sep 16, 2026 Add to My Watchlist

Price and Volume

Volume	4,845
Open	13.62
Bid (Size)	13.44 (100)
Ask (Size)	13.59 (200)
Prev. Close	13.79
Today's Range	13.44 - 13.62
52wk Range	9.770 - 17.79
Shares Outstanding	871,256,270
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy ↗

September 03, 2026

HUTCHMED (NASDAQ:HCM) said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The...

Via MarketBeat

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

September 03, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

Performance

YTD	-1.0%	-1.0%
1 Month	+7.6%	+7.6%
3 Month	+28.8%	+28.8%
6 Month	-5.5%	-5.5%
1 Year	-22.9%	-22.9%

More News

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China

August 30, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

August 27, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®

August 16, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED H1 Earnings Call Highlights ↗

July 30, 2026

Via MarketBeat

HUTCHMED Reports 2026 Interim Results

July 30, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

July 02, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED to Announce 2026 Half-Year Financial Results

June 30, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026

June 24, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

June 11, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

May 21, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

May 21, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

April 29, 2026

From Virtual Investor Conferences

Via GlobeNewswire

HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

April 29, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026

April 23, 2026

From Virtual Investor Conferences

Via GlobeNewswire

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

April 08, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

March 22, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

March 09, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

Intended Retirement of Independent Non-executive Director and changes of composition of board committees

March 06, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Reports 2025 Full Year Results and Business Updates

March 05, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

March 04, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED to Announce 2025 Final Results

February 06, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

January 13, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

January 06, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

Frequently Asked Questions

Is HUTCHMED (China) Limited - American Depositary Shares publicly traded?

Yes, HUTCHMED (China) Limited - American Depositary Shares is publicly traded.

What exchange does HUTCHMED (China) Limited - American Depositary Shares trade on?

HUTCHMED (China) Limited - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for HUTCHMED (China) Limited - American Depositary Shares?

The ticker symbol for HUTCHMED (China) Limited - American Depositary Shares is HCM on the Nasdaq Stock Market

What is the current price of HUTCHMED (China) Limited - American Depositary Shares?

The current price of HUTCHMED (China) Limited - American Depositary Shares is 13.52

When was HUTCHMED (China) Limited - American Depositary Shares last traded?

The last trade of HUTCHMED (China) Limited - American Depositary Shares was at 09/16/26 09:59 AM ET

What is the market capitalization of HUTCHMED (China) Limited - American Depositary Shares?

The market capitalization of HUTCHMED (China) Limited - American Depositary Shares is 11.78B

How many shares of HUTCHMED (China) Limited - American Depositary Shares are outstanding?

HUTCHMED (China) Limited - American Depositary Shares has 12B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.